Want to track IFRX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate.
Zacks | 4 months ago
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
InflaRx (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks | 8 months ago
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ARDS.
Zacks | 11 months ago
InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.27.
Zacks | 1 year ago
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21.
Zacks | 1 year ago
